Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Glesatinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET known ✓ | P08581 | 19/20 | 1.00 |
| ▸ | KDR known ✓ | P35968 | 19/20 | 1.00 |
| ▸ | MST1R known ✓ | Q04912 | 2/20 | 1.00 |
| ▸ | AXL | P30530 | 2/20 | 1.00 |
| ▸ | FLT3 | P36888 | 2/20 | 1.00 |
| ▸ | PLK4 | O00444 | 1/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 1.00 |
| ▸ | FYN | P06241 | 1/20 | 1.00 |
| ▸ | LYN | P07948 | 1/20 | 1.00 |
| ▸ | HCK | P08631 | 1/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 1/20 | 1.00 |
| ▸ | BCR | P11274 | 1/20 | 1.00 |
| ▸ | SRC | P12931 | 1/20 | 1.00 |
| ▸ | ABL2 | P42684 | 1/20 | 1.00 |
| ▸ | FRK | P42685 | 1/20 | 1.00 |
| ▸ | SYK | P43405 | 1/20 | 1.00 |
| ▸ | DDR1 | Q08345 | 1/20 | 1.00 |
| ▸ | MERTK | Q12866 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glesatinib SCHEMBL29351360 | 1.00 | MET (1.00) | METKDRAXLFLT3MST1R | |
| SCHEMBL2673548 | 0.95 | MET (0.91) | METKDRAXLFLT3MST1R | |
| SCHEMBL13167449 | 0.95 | MET (0.91) | METKDRAXLFLT3MST1R | |
| SCHEMBL2536266 | 0.94 | MET (0.89) | METKDRAXLFLT3MST1R | |
| SCHEMBL2670515 | 0.94 | MET (0.89) | METKDRAXLFLT3MST1R | |
| SCHEMBL2670905 | 0.92 | MET (0.86) | METKDRAXLFLT3MST1R | |
| SCHEMBL13926615 | 0.92 | MET (0.85) | METKDRAXLFLT3MST1R | |
| SCHEMBL3613344 | 0.91 | MET (0.84) | METKDRAXLFLT3MST1R | |
| SCHEMBL104141 | 0.90 | MET (0.82) | METKDRAXLFLT3MST1R | |
| SCHEMBL3621731 | 0.90 | MET (0.82) | METKDRAXLFLT3MST1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250169-A1 | AXL Inhibitors for Antiviral Therapy | BERGENBIO ASA (NO) | 2023-08-10 | — | — | US | claimed |
| US-20230151100-A1 | Method of Selecting Patients for Treatment with a Combination of an AXL Inhibitor and an Immune Checkpoint Modulator | BERGENBIO ASA (NO) | 2023-05-18 | — | — | US | claimed |
| CN-116075303-A | Method of selecting patients treated with a combination of an AXL inhibitor and an immune checkpoint modulator | 卑尔根生物股份公司 | 2023-05-05 | — | — | CN | claimed |
| CN-115916344-A | AXL inhibitors for antiviral therapy | 卑尔根生物股份公司 | 2023-04-04 | — | — | CN | claimed |
| EP-4138823-A1 | METHOD OF SELECTING PATIENTS FOR TREATMENT WITH A COMBINATION OF AN AXL INHIBITOR AND AN IMMUNE CHECKPOINT MODULATOR | BerGenBio ASA (NO) | 2023-03-01 | — | — | EP | claimed |
| EP-4132652-A1 | AXL INHIBITORS FOR ANTIVIRAL THERAPY | BerGenBio ASA (NO) | 2023-02-15 | — | — | EP | claimed |
| EP-4125908-A1 | COMBINATION THERAPY COMPRISING AN AXL INHIBITOR | BerGenBio ASA (NO) | 2023-02-08 | — | — | EP | claimed |
| WO-2021214492-A1 | METHOD OF SELECTING PATIENTS FOR TREATMENT WITH A COMBINATION OF AN AXL INHIBITOR AND AN IMMUNE CHECKPOINT MODULATOR | BERGENBIO ASA (NO) | 2021-10-28 | — | — | WO | claimed |
| WO-2021191197-A1 | COMBINATION THERAPY COMPRISING AN AXL INHIBITOR | BERGENBIO ASA (NO) | 2021-09-30 | — | — | WO | claimed |
| WO-2021032883-A1 | COMBINATION THERAPY OF A PATIENT SUBGROUP | BERGENBIO ASA (NO) | 2021-02-25 | — | — | WO | claimed |
| US-20060287343-A1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE, INC. | 2006-12-21 | — | — | US | claimed |
| EP-4543449-A1 | DOSAGE REGIMEN FOR AXL INHIBITOR | BerGenBio ASA (NO) | 2025-04-30 | — | — | EP | disclosed |
| US-20240173403-A1 | Combination of AXL Antibodies and ACE Inhibitors in the Treatment of Fibrosis | BERGENBIO ASA (NO) | 2024-05-30 | — | — | US | disclosed |
| EP-4314064-A1 | COMBINATION OF AXL ANTIBODIES AND ACE INHIBITORS IN THE TREATMENT OF FIBROSIS | BerGenBio ASA (NO) | 2024-02-07 | — | — | EP | disclosed |
| WO-2023247769-A1 | DOSAGE REGIMEN FOR AXL INHIBITOR | BERGENBIO ASA (NO) | 2023-12-28 | — | — | WO | disclosed |
| US-20090286984-A1 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | Mirati Therapeutics, Inc. | 2009-11-19 | — | — | US | disclosed |
| US-20090286984-A1 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | Mirati Therapeutics, Inc. | 2009-11-19 | — | — | US | disclosed |
| US-20090286984-A1 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | Mirati Therapeutics, Inc. | 2009-11-19 | — | — | US | disclosed |
| WO-2009026720-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING FUSED HETEROCYCLIC KINASE INHIBITORS | METHYLGENE INC. (CA) | 2009-03-05 | — | — | WO | disclosed |
| US-20060287343-A1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE, INC. | 2006-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286984-A1 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | MAP3K19, MAP3K9, MAP4K2 | MET 1062/4885KDR 526/4885MST1R 759/4885 |
| US-20060287343-A1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | HGF, MET, FLT1 | MET 2/4885KDR 4/4885MST1R 44/4885 |
| US-20230250169-A1 | AXL Inhibitors for Antiviral Therapy | FLT3, AXL, SARS1 | MET 60/4885KDR 166/4885MST1R 30/4885 |
| US-20230151100-A1 | Method of Selecting Patients for Treatment with a Combination of an AXL Inhibitor and an Immune Checkpoint Modulator | STK11, MERTK, AXL | MET 167/4885KDR 834/4885MST1R 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.